Fasting and post-prandial glycemia and their correlation with glycated hemoglobin in Type 2 diabetes

2006 ◽  
Vol 29 (7) ◽  
pp. 619-624 ◽  
Author(s):  
M. Monami ◽  
C. Lamanna ◽  
L. Lambertucci ◽  
R. Longo ◽  
C. Cocca ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycated Hemoglobin

scholarly journals Glycemic variability and cardiovascular disease in patients with type 2 diabetes

2021 ◽  
Vol 9 (1) ◽  
pp. e002032
Author(s):  
Marcela Martinez ◽  
Jimena Santamarina ◽  
Adrian Pavesi ◽  
Carla Musso ◽  
Guillermo E Umpierrez
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Glycated Hemoglobin ◽  
Glucose Monitoring ◽  
Glycemic Variability ◽  
Cardiovascular Complications ◽  
Glucose Levels ◽  
Increased Risk ◽  
Patients With Diabetes

Glycated hemoglobin is currently the gold standard for assessment of long-term glycemic control and response to medical treatment in patients with diabetes. Glycated hemoglobin, however, does not address fluctuations in blood glucose. Glycemic variability (GV) refers to fluctuations in blood glucose levels. Recent clinical data indicate that GV is associated with increased risk of hypoglycemia, microvascular and macrovascular complications, and mortality in patients with diabetes, independently of glycated hemoglobin level. The use of continuous glucose monitoring devices has markedly improved the assessment of GV in clinical practice and facilitated the assessment of GV as well as hypoglycemia and hyperglycemia events in patients with diabetes. We review current concepts on the definition and assessment of GV and its association with cardiovascular complications in patients with type 2 diabetes.

scholarly journals MOLECULAR ASPECT CORRELATION BETWEEN GLYCATED HEMOGLOBIN (HBA1C), PROTHROMBIN TIME (PT) AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) ON TYPE 2 DIABETES MELLITUS (T2DM) (Aspek molekuler Hubungan Kadar Hemoglobin Terglikasi (HbA1c), Prothrombin Time (PT) dan Activated Partial Thromboplastin Time (APTT) di Diabetes Melitus Tipe 2)

2018 ◽  
Vol 23 (1) ◽  
pp. 1
Author(s):  
Indranila KS
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Prothrombin Time ◽  
Partial Thromboplastin Time ◽  
Glycated Hemoglobin ◽  
Activated Partial Thromboplastin Time ◽  
Molecular Aspect ◽  
Diabetes Melitus

Diabetes Melitus (DM) memerlukan pengendalian glikemia yang dapat diketahui dengan melakukan pemeriksaan hemoglobinterglikasi (HbA1c). Semakin tinggi kadar hemoglobin terglikasi (HbA1c), semakin tidak terkendali kadar gula darah pasien DM tipe2. Hal ini dapat menyebabkan terjadinya proses hiperkoagulasi dan gangguan mikrovaskular maupun makrovaskular. PemeriksaanProtrombin Time (PT) dan Activated Partial Thromboplastin Time (APTT) diharapkan dapat mendeteksi secara dini adanya gangguankoagulasi di pasien DM tipe 2. Penelitian potong lintang terhadap 72 orang pasien DM tipe 2 yang berusia diatas 18 tahun diperiksakadar HbA1c dan dikaji koagulasi (PT dan APTT). Pasien dengan penyakit penyerta seperti anemia dan kelainan hemoglobin, keganasanatau kelainan hematologis, pasca bedah, hipertiroid, perempuan hamil, riwayat penyakit hati dan pasien yang mengkonsumsi obatobatanyang mengganggu fungsi koagulasi dikeluarkan dari penelitian ini. Uji normalitas data menggunakan Kolmogorov-Smirnovdan analisis hubungan menggunakan uji Pearson. Analisis kenasaban terdapat hubungan antara kadar hemoglobin terglikasi denganProthrombin Time negatif lemah (r= -0,179; p=0,132) dan dengan Activated Partial Thromboplastin Time positif sangat lemah (r=0,016;p=0,892). Berdasarkan telitian ini terdapat hubungan negatif lemah yang bermakna antara kadar hemoglobin terglikasi dengan PTdan hubungan positif sangat lemah yang tidak bermakna dengan Activated Partial Thomboplastin Time.

scholarly journals Quality of ejaculate of male patients with type 2 diabetes mellitus (DM), vaccinated with GamCovidVac (Sputnik V)

2022 ◽  
Vol 24 (5) ◽  
pp. 422-426
Author(s):  
D. I. Esaulenko ◽  
R. R. Rozhivanov ◽  
V. V. Shishkina
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Testosterone Level ◽  
Glycated Hemoglobin ◽  
Sperm Count ◽  
Total Testosterone ◽  
Male Patients

Background: New coronavirus infection (Covid-19) in patients with diabetes type 2 mellitus (DM) often has severe clinical course and manifestation. This comorbidity is a reasonable indication for vaccination. Male patients are often concerned about the vaccination impact on their fertility, so the current research of this issue seems to be essential and relevant.Aims: To evaluate the quality of ejaculate in type 2 diabetes mellitus (DM) patients, vaccinated by GamCovidVac (Sputnik V).Materials and Methods: The pilot observational prospective study included 30 males with type 2 diabetes mellitus (DM). The study continued from February 2021 till June 2021. The research design involved medical history analysis, glycated hemoglobin (HbA1c) tests, total testosterone level in blood measurement, semen analysis (sperm count test). Group comparison was performed by Wilcoxon Signed Ranks Test. The differences were considered statistically significant at p<0.05.Results: After vaccination 19 patients (63%) demonstrated a temperature rise which lasted for 2 days; 26 patients (87%) complained of tenderness in the injections site which lasted up to 5 days. Though a few patients reported general somatic side effects after the vaccination, there have been no statistically significant deviations in sperm count, viability, function and morphology. The levels of glycated hemoglobin and total testosterone remained unchanged.Conclusion: The study revealed no negative impact of GamCovidVac on ejaculate quality, total testosterone level and compensation of carbohydrate metabolism.

Sign in / Sign up

Export Citation Format

Share Document